Amgen has achieved a significant milestone as its lung cancer treatment, tarlatamab, secured approval from China’s National Medical Products Administration. This announcement was made public by BeOne Medicines, Amgen’s development and commercialization partner, through a post on the social media platform WeChat on Friday. The drug targets adults suffering from extensive-stage small cell lung cancer, a particularly aggressive form of the disease that has progressed despite prior chemotherapy treatments.
Tarlatamab is a form of targeted immunotherapy designed to harness the body’s immune system to combat cancer cells. It belongs to Amgen’s innovative pipeline of bispecific antibodies, which function by simultaneously binding to cancer cells and immune cells. This dual binding mechanism effectively brings immune cells into close proximity with cancer cells, enabling the immune system to identify and destroy the malignant cells more efficiently.
In the United States, Amgen markets this therapy under the brand name Imdelltra. The drug’s approval in China marks a crucial expansion into one of the world’s largest pharmaceutical markets, potentially offering new hope to patients with limited treatment options for this hard-to-treat cancer. Meanwhile, both Amgen and BeOne Medicines have remained tight-lipped regarding the specific launch timeline and pricing strategy for the Chinese market.
Industry analysts on Wall Street have expressed optimism about tarlatamab’s commercial prospects, estimating that it could generate annual sales exceeding $2 billion for Amgen. This projection underscores the growing demand for advanced cancer therapies globally and highlights the strategic importance of China’s regulatory approval in Amgen’s broader market expansion plans.
